Clinical Trials
6
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:5
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (83.3%)Phase 3
1 (16.7%)A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Shandong Boan Biotechnology Co., Ltd
- Target Recruit Count
- 70
- Registration Number
- NCT06927349
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Non-Small Cell Lung CancerPancreatic AdenocarcinomaBreast CancerMelanoma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Shandong Boan Biotechnology Co., Ltd
- Target Recruit Count
- 167
- Registration Number
- NCT06596915
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Phase 3
Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Shandong Boan Biotechnology Co., Ltd
- Target Recruit Count
- 510
- Registration Number
- NCT06022861
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
A Study of BA1202 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Shandong Boan Biotechnology Co., Ltd
- Target Recruit Count
- 78
- Registration Number
- NCT05909241
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Shandong Boan Biotechnology Co., Ltd
- Target Recruit Count
- 177
- Registration Number
- NCT05650242
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- Next
News
No news found